Company intelligence / Profile preview

PnuVax

Kingston, Ontario, Canadapnuvax.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PnuVax has developed a lower-cost pneumococcal conjugate vaccine and an inactivated cell-culture-based yellow fever vaccine. Both are being advanced toward regulatory approval with the aim of providing affordable access in underserved regions. The company also has monoclonal antibody candidates for coronaviruses and continues to develop additional vaccines targeting neglected diseases.

Therapeutic areas: Infectious Diseases
Modalities: VaccineMonoclonal antibodyRecombinant proteinBiologic
Industry: Biotech

Drug pipeline

1 asset

Inactivated yellow fever vaccine

Pre-clinical

Indications: Yellow fever

Partnerships

Partnerships mentioned with organizations focused on global health access such as GAVI and UNICEF markets; specific pharma partners not named.

Beyond the preview

Go deeper on PnuVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PnuVax.

Explore the full profile